Swedbank AB Grows Position in Henry Schein, Inc. $HSIC

Swedbank AB lifted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,312,312 shares of the company’s stock after purchasing an additional 12,741 shares during the quarter. Swedbank AB’s holdings in Henry Schein were worth $99,185,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Artisan Partners Limited Partnership grew its position in shares of Henry Schein by 5.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after buying an additional 370,837 shares during the period. Invesco Ltd. lifted its position in Henry Schein by 4.1% during the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock valued at $314,043,000 after acquiring an additional 184,763 shares during the period. Dimensional Fund Advisors LP lifted its position in Henry Schein by 6.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,596,168 shares of the company’s stock valued at $172,304,000 after acquiring an additional 159,087 shares during the period. Ameriprise Financial Inc. boosted its stake in Henry Schein by 11.3% during the third quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock worth $167,453,000 after acquiring an additional 256,156 shares in the last quarter. Finally, Snyder Capital Management L P boosted its stake in Henry Schein by 18.6% during the third quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company’s stock worth $88,562,000 after acquiring an additional 209,123 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Insider Buying and Selling

In related news, CEO Thomas C. Popeck sold 1,355 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the sale, the chief executive officer owned 86,182 shares in the company, valued at approximately $6,273,187.78. This trade represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Stanley M. Bergman sold 43,812 shares of Henry Schein stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the sale, the chief executive officer directly owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. This trade represents a 10.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 105,911 shares of company stock valued at $8,574,982 in the last ninety days. Corporate insiders own 0.89% of the company’s stock.

Trending Headlines about Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q1 results beat expectations: HSIC reported $1.32 EPS on $3.37B revenue, topping consensus and showing 6.3% revenue growth and margin improvement — a core reason investors bought the stock after the print. Henry Schein Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dental strength and margin expansion were highlighted by management and reporters, supporting the beat and the company’s message of market‑share gains. Reuters: Henry Schein reaffirms annual profit forecast, beats Q1 estimates
• Positive Sentiment: Analyst commentary and screens emphasize HSIC’s value characteristics (attractive P/E, stable cash flows), with Zacks flagging the stock as a strong value pick for some investors. Here’s Why Henry Schein (HSIC) is a Strong Value Stock
• Neutral Sentiment: Company reaffirmed FY‑2026 EPS guidance (5.230–5.370) and revenue range roughly in line with consensus — guidance was maintained, not raised, so this is reassuring but not a catalyst. Press release / guidance
• Neutral Sentiment: Earnings call transcript and slide deck are available for deeper detail on segment trends and margin drivers — useful for investors doing diligence. Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Several roundup pieces note mixed analyst views on HSIC — debate centers on execution of margin improvement and growth sustainability rather than any single, clear directional factor. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: At least one shop cut its price target (Mizuho lowered PT from $88 to $82 and set a neutral rating), which can pressure the stock via reduced analyst upside and sentiment. Tickerreport: Mizuho price target cut
• Negative Sentiment: Despite the beat, the stock is trading lower with above‑average volume (investors appear to be selling into the print, possibly locking in gains or reacting to the mixed analyst tone). MarketWatch: stock underperforms peers

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $72.44 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.36. The firm has a market cap of $8.31 billion, a price-to-earnings ratio of 21.89, a price-to-earnings-growth ratio of 2.20 and a beta of 0.82. The business has a 50-day simple moving average of $76.32 and a two-hundred day simple moving average of $75.00. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.29.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter last year, the firm posted $1.15 EPS. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts expect that Henry Schein, Inc. will post 5.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on HSIC shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research note on Monday. Citigroup started coverage on Henry Schein in a research report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price target on the stock. Mizuho cut their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research note on Wednesday. Robert W. Baird set a $97.00 price objective on Henry Schein in a research report on Wednesday. Finally, Wall Street Zen cut Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $86.83.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.